Researchers at MD Anderson Cancer Center identified a pathway by which cancer cells spread in the brain, opening up new possibilities for treatment. They found that the gene WNT5A enables glioma stem cells to transition into GdECs, leading to aggressive tumor growth and disease recurrence.
A study at the University of Texas MD Anderson Cancer Center found that the tumor suppressor gene quaking (QKI) plays a major regulator role in cancer stem cells of glioblastoma, the deadliest type of brain tumor. QKI impacts cellular activity called endocytosis, allowing glioma stem cells to thrive in inhospitable sites.
A study by the University of Texas MD Anderson Cancer Center found that 81% of indoor tanning facilities complied with the Texas ban on indoor tanning for those under 18. The study also showed that daily use practices exceeded FDA guidelines, and most facilities indicated that burns are possible with indoor tanning.
Researchers at MD Anderson Cancer Center have developed a new tool to predict lung cancer risk in never, light, and heavy smokers. By incorporating various risk factors, the model can better classify those in greatest need of lung cancer screening, thereby reducing unnecessary screenings and false positives.
A Phase III trial found ribociclib improved PFS of post-menopausal women with hormone receptor-positive metastatic breast cancer by 44 percent compared to hormone therapy alone. The study also showed a higher ORR in patients receiving ribociclib, with serious adverse events occurring less than five percent overall.
A new study from MD Anderson found substantial variation in the costs of breast cancer treatment for different chemotherapy regimens, with varying prices by up to $20,354. The researchers suggest that informed choice of chemotherapy could impact costs nationally by $1 billion annually.
Researchers discovered a combination of two inhibitor drugs that can stop CML completely and significantly lower treatment costs. The study, published in Science Translational Medicine, found encouraging response and cure rates for both chronic phase and blast crisis, offering new hope for patients.
A new study reveals that chromosomal changes in breast cancer occur in short, punctuated 'bursts' at the earliest stages of tumor growth, contradicting the traditional gradual acquisition model. This finding has significant implications for diagnosis and treatment, suggesting a potential new approach to clinical management.
Researchers analyzed tumor biopsies from 53 melanoma patients treated with immune checkpoint inhibitors to predict treatment response. The study found that adaptive immune responses, such as killer T cells, were significantly higher in responders after treatment began.
A study at The University of Texas MD Anderson Cancer Center reveals protein ZMYND8's ability to block metastasis-linked gene expression in prostate cancer. ZMYND8 cooperates with histone mark eraser JARID1D to suppress metastasis-linked genes.
A study at the University of Texas MD Anderson Cancer Center found that genetic mutations in DNA mismatch repair deficiency (dMMR) are present in 15% of colorectal cancer cases. The study identified MSH2 and MSH6 as the most commonly affected genes, providing a new approach to diagnosis and treatment using precision medicine.
Researchers developed a rapid screening technique to analyze human tumors transplanted into mice, identifying WDR5 as a new culprit in pancreatic cancer. The study found that WDR5 protects tumors from DNA damage and works with the previously known cancer-promoting gene Myc to help tumors thrive.
A new study finds that a shorter radiation course with higher doses per fraction is equivalent to a longer, lower-dose course in terms of cosmetic, functional, and pain outcomes. The results support the use of hypofractionated whole-breast irradiation as the preferred treatment for early-stage breast cancer patients.
A randomized Phase III study found nearly 81% of patients in the inotuzumab ozogamicin group achieved complete remission, compared to 31-41% with standard therapies. The drug enabled 41% of patients to proceed with stem cell transplants, increasing their chances of a curative treatment.
A new study led by MD Anderson Cancer Center found an eight-month progression-free survival benefit in patients treated with local consolidative therapy, a significant shift in clinical care for thousands of lung cancer patients. The treatment improved outcomes for those with oligometastases, defined as three or fewer sites of metastasis.
A Phase I/II clinical trial found that nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of PD-L1 marker presence. The treatment was well-tolerated and showed a median survival of at least one year for 45.6% of patients.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in the treatment of endometrial and ovarian cancers. A Phase II trial combining everolimus, letrozole, and metformin shows a 67 percent clinical benefit rate for patients with recurrent endometrioid endometrial cancer. Additionally, hormonal maintenance therap...
A Phase II clinical trial conducted by MD Anderson Cancer Center found that nivolumab significantly improves outcomes for patients with squamous cell carcinoma of the anal canal, with a control rate of 70%. The study enrolled 39 patients and demonstrated efficacy in both HIV-positive and non-HIV positive populations.
A new study from MD Anderson Cancer Center found substantial variation in costs of breast cancer treatment for different chemotherapy regimens, with insurer costs varying by as much as $20,354. Choosing equally effective but less costly regimens could impact the cost of breast cancer care nationally by $1 billion every year.
Researchers identified 2,314 genetic changes in polyps and adjacent mucosa, revealing potential drug targets for colorectal cancer prevention. The study also found similarities between premalignant and cancerous tissue, suggesting that polyps with more genetic changes may be more likely to develop into CRC.
Researchers found more than half of the genes studied showed sex-biased signatures in certain cancer types, revealing two sex-effect groups associated with distinct incidence and mortality profiles. These findings lay a critical foundation for precision cancer medicine that is sex-specific.
Researchers identified three subtypes of ACC with distinct clinical outcomes and molecular alterations. The study also found novel ACC driver genes and suggests that inhibiting whole genome doubling could slow tumor growth. These findings may inform therapeutic decisions and lead to significant advances in patient outcomes.
A study by researchers at the University of Texas M. D. Anderson Cancer Center found that gene therapy may be able to reverse cancer-related nerve pain. The treatment, which involves transferring a gene called KCC2 into the spinal canal, restored chloride levels and eliminated pain hypersensitivity in rats.
A new study published in Cell Reports identifies microRNA molecule miR551b as a promising candidate biomarker and therapeutic target for treating ovarian cancers. The research found that targeting miR551b expression could block STAT3 activity, offering potential for treating the most common and deadly form of ovarian cancer.
Researchers discovered TJP1's role in identifying patients most likely to benefit from proteasome inhibitors, with low TJP1 levels associated with resistance. The study provides a rationale for using TJP1 as a biomarker for personalized treatment approaches.
Researchers developed Monovar to analyze multiple single cells, detecting subtle DNA changes that can inform personalized medicine and cancer care. The method shows promise for diagnosing and treating various diseases, including pre-natal genetic diagnosis.
A study at the University of Texas M. D. Anderson Cancer Center found that normal liver cells metabolize dietary fructose differently than cancerous cells, revealing a potential diagnostic marker for liver cancer. The researchers discovered a gene called KHK that is expressed differently in healthy and tumor tissues.
A phase I study of LOXO-101 demonstrated efficacy in reducing tumors in six patients with TRK fusion-positive cancers, including sarcoma, thyroid, and non-small cell lung. The study showed significant tumor regression in all six patients, with one patient experiencing a 17% tumor reduction.
Researchers at MD Anderson Cancer Center reported encouraging correlations between immunologic biomarkers and responses to treatment with nivolumab in the first-ever phase II clinical trial for metastatic squamous cell carcinoma of the anal canal. Five patients treated with nivolumab experienced significant tumor size reductions.
A study published by the University of Texas M.D. Anderson Cancer Center found a link between obesity and kidney cancer recurrence, with leptin receptors playing a key role in tumor formation. The research suggests that obesity may also impact prognosis for patients with renal cell carcinoma.
A study from MD Anderson Cancer Center reveals a strong association between hepatitis C and certain head and neck cancers, such as oropharyngeal and nonoropharyngeal cancers. The findings have significant implications for screening and treatment of both conditions.
A new breast cancer staging system, Neo-Bioscore, incorporates HER2 status to provide more precise prognostic stratification of all breast cancer subtypes. The system improves prognosis and identifies patients in greatest need of additional therapy.
Physician-scientists Ethan Dmitrovsky and Waun Ki Hong recognized for their efforts in cancer prevention and control. Dmitrovsky's work on retinoids has led to a significant impact on leukemia treatment, while Hong's research in cancer chemoprevention and personalized therapies has advanced the field.
A new study from the University of Texas M. D. Anderson Cancer Center found that neurofeedback significantly reduces chronic pain and improves quality of life in cancer patients with chemotherapy-induced neuropathy. The treatment, which uses electroencephalogram biofeedback to modify brain activity, showed a 73% improvement rate in pai...
Researchers found PGK1 plays a key role in coordinating cellular processes for cancer metabolism and brain tumor formation. The enzyme promotes energy production through the Warburg effect, leading to rapid cancer growth.
A study by the University of Texas M.D. Anderson Cancer Center reveals that adult stem cells in the prostate basal cell layer express genes similar to those found in deadly prostate cancer, offering a potential new line of treatment for highly aggressive and therapy-resistant forms.
The University of Texas MD Anderson Cancer Center received $14 million in CPRIT research funding to recruit three cancer scientists, including two senior researchers and a tenure-track faculty member. This funding supports the institution's goal of attracting top research talent to advance cancer research.
A recent clinical study found that ONC201 caused cell death in various tumor types, even when the p53 protein was mutated or deleted. The drug has shown promise in treating hematological malignancies, including leukemia and lymphoma patients, with clinical trials recently initiated.
Researchers at MD Anderson Cancer Center proposed a new staging system for HPV-related oropharyngeal cancer, which better separates patients with different survival rates. The new groupings were proven to have greater predictive power than the current system, particularly in identifying stage III disease with a high risk of death.
Researchers will compare surgery and active surveillance in women with low-grade DCIS, evaluating quality of life and psychosocial outcomes. The four-year study aims to answer whether invasive surgery is necessary for non-fatal disease.
A multi-center study identified distinct molecular and clinical features in diffuse glioma patients, shedding light on disease progression. The findings may lead to improved treatment outcomes by enabling precise prediction of tumor growth and response to therapy.
A new procedure, Targeted Axillary Dissection (TAD), reduces need for invasive surgery in select patients with axillary metastasis. TAD involves removing sentinel lymph nodes and additional cancerous lymph nodes found during diagnosis, improving staging accuracy and reducing complications.
A study published in Nature Immunology identified Trabid, a protein regulator, as a key component in regulating interleukin genes and promoting autoimmune inflammation in multiple sclerosis patients. This finding suggests that Trabid may be a potential therapeutic target for treating inflammatory diseases such as MS.
A new study suggests that combining PARP inhibitors with c-MET inhibitors may improve treatment outcomes for patients with breast cancer and high c-MET expression levels.
A multi-institutional international study has revealed new information about the interaction between long non-coding RNAs and HIF-1 signaling pathways in triple-negative breast cancer. The study identifies four previously unknown phosphorylation sites, which predict a worse outcome for TNBC patients, suggesting that these sites could s...
A recent study at MD Anderson Cancer Center found that dietary sugar, particularly fructose, can increase the risk of breast cancer tumors and lung metastasis in mice. The research suggests that high sugar intake activates an inflammatory pathway called 12-LOX, leading to increased tumor growth and spread.
Researchers at MD Anderson Cancer Center identified myeloid-derived suppressor cells (MDSCs) as a key player in advanced prostate cancer progression. Depletion of MDSCs and blocking specific signaling pathways showed promise in suppressing tumor growth, paving the way for potential therapeutic opportunities.
Researchers at MD Anderson Cancer Center have developed a new liquid biopsy technique that can analyze tumor genes from blood samples using exosomes, providing a non-invasive alternative to traditional biopsies. The approach has the potential to improve prognosis, guide targeted therapy, and monitor treatment progress.
A new study from MD Anderson Cancer Center found that delaying chemotherapy after surgery increases the risk of death for breast cancer patients, particularly those with triple-negative breast cancer. Patients who start treatment within 90 days have a lower risk of death compared to those who delay it.
A new study from the University of Texas MD Anderson Cancer Center found that mastectomy plus reconstruction has the highest rate of complications and complication-related costs among guideline-concordant therapies for early breast cancer. The study also revealed that this treatment option is the most expensive in younger patients, wit...